Name | Salinomycin sodium salt |
Synonyms | Salinomycin sodium Salinomycin-Natrium Salinomycin sodium salt Salinomycin, Sodium Salt Salinomycin sodium premix Salinomycin, monosodium salt SALINOMYCIN SODIUM SALT 2.5-HYDRATE salinomycin monosodium salt hydrate Salinomycin hydrate monosodium salt SALINOMYCIN SV SODIUM SALT 2,5-HYDRATE (2R)-2-[(5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-Ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5.3]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid |
CAS | 55721-31-8 |
EINECS | 611-309-0 |
InChI | InChI=1/C42H70O11.Na/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33;/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47);/q;+1/p-1/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-;/m0./s1 |
Molecular Formula | C42H71NaO12 |
Molar Mass | 791 |
Melting Point | 140-142° |
Specific Rotation(α) | D25 -37° (c = 1 in ethanol) |
Solubility | Soluble in DMSO. |
Appearance | Brown to Dark Brown Solid |
Color | White |
Merck | 13,8415 |
BRN | 4901827 |
Storage Condition | APPROX 4°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
Physical and Chemical Properties | White or light yellow crystalline powder, micro-specific odor, melting point 140-142 ℃. Soluble in acetone, chloroform, benzene, ethyl acetate, ethyl ether and methanol, almost insoluble in water. Rats by mouth LD5070-100mg/kg, mice by mouth LD5050mg/kg, chicken LD50150mg/kg. |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC 50 24h : 13.8 μM, IC 50 48h : 6.888 μM and IC 50 72h : 4.382 μM for A2780 cell lines), (IC 50 24h : 12.7 μM, IC 50 48h : 9.869 μM and IC 50 72h : 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor. |
In vivo study | Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice. |
Hazard Symbols | T - Toxic |
Risk Codes | 25 - Toxic if swallowed |
Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | 2811 |
WGK Germany | 3 |
Hazard Class | 6.1 |
Packing Group | III |
biological activity | Salinomycin sodium salt (Salinomycin sodium), a potassium ionophore-based antibiotic, it is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt acts on the Wnt/Fzd/LRP complex, blocking Wnt-induced LRP6 phosphorylation, resulting in LRP6 protein degradation. Salinomycin sodium salt selectively inhibits human tumor stem cells. |
Target | Wnt/β-catenin |
uses | sodium salinomycin is a safe and effective anti-coccidiosis drug, which also has inhibitory effect on most Gram-positive bacteria, tender Ehrlich, poison Ehrlich, giant Ehrlich, pile of Ehrlich, and Haugh coccidia were all effective. Can be used for chicken feed, the amount of 50-60g/t, the egg production period is disabled, the withdrawal period of 5 days. Horse animals are not to be used, and will be lethal after use; It is prohibited to use together with tyramine and cardamomycin. |
production method | is produced by fermentation of Streptomyces albus. |